• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[The guidelines for the diagnosis and management of multiple myeloma in China (2015 revision) : interpretation of initial treatment].

作者信息

Chen Xiequn

出版信息

Zhonghua Nei Ke Za Zhi. 2016 Feb;55(2):92-3. doi: 10.3760/cma.j.issn.0578-1426.2016.02.003.

DOI:10.3760/cma.j.issn.0578-1426.2016.02.003
PMID:26875573
Abstract
摘要

相似文献

1
[The guidelines for the diagnosis and management of multiple myeloma in China (2015 revision) : interpretation of initial treatment].《中国多发性骨髓瘤诊治指南（2015年修订版）：初始治疗解读》
Zhonghua Nei Ke Za Zhi. 2016 Feb;55(2):92-3. doi: 10.3760/cma.j.issn.0578-1426.2016.02.003.
2
[The guidelines for the diagnosis and management of multiple myeloma in China (2015 revision) : interpretation of the treatment of relapsing and refractory multiple myeloma].中国多发性骨髓瘤诊断与治疗指南（2015年修订版）：复发/难治性多发性骨髓瘤治疗解读
Zhonghua Nei Ke Za Zhi. 2016 Feb;55(2):93-4. doi: 10.3760/cma.j.issn.0578-1426.2016.02.004.
3
[The guidelines for the diagnosis and management of multiple myeloma in China (2015 revision) : interpretation of diagnosis].《中国多发性骨髓瘤诊治指南（2015年修订版）：诊断解读》
Zhonghua Nei Ke Za Zhi. 2016 Feb;55(2):91-2. doi: 10.3760/cma.j.issn.0578-1426.2016.02.002.
4
[The guidelines for the diagnosis and management of multiple myeloma in China (2015 revision) : interpretation of response criteria].《中国多发性骨髓瘤诊治指南（2015年修订版）：疗效标准解读》
Zhonghua Nei Ke Za Zhi. 2016 Feb;55(2):94-6. doi: 10.3760/cma.j.issn.0578-1426.2016.02.005.
5
[Interpretation of minimal residual disease monitoring for response evaluation in "the guidelines for the diagnosis and management of multiple myeloma in China(2020 revision)"].《解读<中国多发性骨髓瘤诊断与治疗指南（2020年修订版）>中微小残留病监测用于疗效评估》
Zhonghua Nei Ke Za Zhi. 2020 May 1;59(5):332-334. doi: 10.3760/cma.j.cn112138-20200217-00084.
6
[Best wishes to the guidelines for the diagnosis and management of multiple myeloma in China (2020 revision)].[祝《中国多发性骨髓瘤诊断与治疗指南（2020年修订版）》顺利]
Zhonghua Nei Ke Za Zhi. 2020 May 1;59(5):329-331. doi: 10.3760/cma.j.cn112138-20200309-00208.
7
[Interpretation of diagnosis of multiple myeloma in the guidelines for the diagnosis and management of multiple myeloma in China (2022 revision)].[中国多发性骨髓瘤诊断与治疗指南（2022年修订版）中多发性骨髓瘤诊断的解读]
Zhonghua Nei Ke Za Zhi. 2022 May 1;61(5):463-465. doi: 10.3760/cma.j.cn112138-20220316-00182.
8
[Interpretation of treatment of relapsed/refractory multiple myeloma patients in the guidelines for the diagnosis and management of multiple myeloma in China(2022 revision)].[《中国多发性骨髓瘤诊断与治疗指南（2022年修订版）》中复发/难治性多发性骨髓瘤患者的治疗解读]
Zhonghua Nei Ke Za Zhi. 2022 May 1;61(5):469-473. doi: 10.3760/cma.j.cn112138-20220414-00278.
9
[Interpretation of treatment for newly diagnosed multiple myeloma patients in the guidelines for the diagnosis and management of multiple myeloma in China (2022 revision)].
Zhonghua Nei Ke Za Zhi. 2022 May 1;61(5):465-469. doi: 10.3760/cma.j.cn112138-20220309-00162.
10
[The guidelines for the diagnosis and management of multiple myeloma in China (2017 revision)].中国多发性骨髓瘤诊断与治疗指南（2017年修订版）
Zhonghua Nei Ke Za Zhi. 2017 Nov 1;56(11):866-870. doi: 10.3760/cma.j.issn.0578-1426.2017.11.021.

引用本文的文献

1
Significance of the peripheral blood Treg/Th17 ratio as a prognostic immune biomarker in newly diagnosed multiple myeloma and its correlation with 1q21 gain/amplification.外周血Treg/Th17比值作为新诊断多发性骨髓瘤预后免疫生物标志物的意义及其与1q21获得/扩增的相关性。
Front Immunol. 2025 May 29;16:1595613. doi: 10.3389/fimmu.2025.1595613. eCollection 2025.